









Markets
/
Stocks
/
nasdaq-lxrx
/

Lexicon Pharmaceuticals Inc

LXRX

View Detailed Chart

1.070USD

0.000

Close 08/01, 16:00（ET）Quotes delayed by 15 min

388.60MMarket Cap

LossP/E TTM



Lexicon Pharmaceuticals Inc

1.070

0.000

Overview Company Financials

Financials

Intraday

30m

Today

0.00%

5 Days

-2.73%

1 Month

+18.76%

6 Months

+47.10%

Year to Date

+44.89%

1 Year

-36.87%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts

BUY

Current Rating

2.580

Target Price

141.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Lexicon Pharmaceuticals Inc

LXRX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(3)

Neutral(4)

Buy(5)

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.063

Neutral

RSI(14)

52.342

Neutral

STOCH(KDJ)(9,3,3)

21.774

Neutral

ATR(14)

0.105

High Vlolatility

CCI(14)

-77.960

Neutral

Williams %R

83.721

Oversold

TRIX(12,20)

1.028

Sell

StochRSI(14)

69.259

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.064

Buy

MA10

1.119

Sell

MA20

1.123

Sell

MA50

0.893

Buy

MA100

0.710

Buy

MA200

0.821

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Ticker SymbolLXRX

CompanyLexicon Pharmaceuticals Inc

CEOMr. Michael Exton

Websitehttps://www.lexpharma.com/